Fumitremorgin C, a highly specific ABCG2 inhibitor, is too neurotoxic for clinical use; despite their effectiveness in vitro, these inhibitors are scarcely suitable for clinical application for cancer treatment because of their intolerable toxicities. The gene discussed is ABCG2; the disease is cancer.